October 4, 2021

October 4, 2021

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.

October 4, 2021

EHA 2021 Top Pick #11: Fixed-Duration Ibrutinib and Venetoclax (I+V) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First Line (1L) Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 GLOW Study

Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib inhibits chronic lymphocytic leukemia or CLL cells’ proliferation and gets the cancer cells out of their protective niches in the nodes and bone marrow and into the blood stream

October 4, 2021

ASCO 2021 Top Pick #10: Survival trends in chronic lymphocytic leukemia in the era of oral targeted therapies in the United States: SEER database analyses (1985 to 2017)

In this paper presented at ASCO 2021 by Alrawashdh et al, we learn about historical survival trends for CLL patients over the 22 years between 1985 and 2017.

October 4, 2021

EHA 2021 Top Pick #9: Ibrutinib Treatment in the First Line Setting for Patients with Chronic Lymphocytic Leukemia. Up to 7 Years of Follow-Up in the RESONATE-2 Study

Dr. Paolo Ghia, at the European Hematology Association (EHA) 2021 virtual annual meeting, presented the results of seven years of follow-up of treatment-naïve chronic lymphocytic leukemia patients treated with ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor.

October 4, 2021

ASCO 2021 Top Pick #8: First In-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i) in Patients with Relapsed/Refractory (R/R) CLL and Other Hematologic Malignancies

In this ASCO 2021 abstract by Ailawadhi from Mayo and others, we learn of the first in human trial of a novel BCL-2 inhibitor (BCL-2i), lisaftoclax or APG-2575.

October 4, 2021

EHA 2021 Top Pick #7: Long Term Results of a Phase I/Ib Study of Ibrutinib in Combination with Umbralisib for Patients with Relapsed/Refractory (R/R) CLL (Chronic Lymphocytic Leukemia) or MCL (Mantle Cell Lymphoma)

Dr. Matt Davids of Dana Farber presented this abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021) that updated the results of combining two different oral targeted therapies that both block B-cell receptor (BCR) signaling: Ibrutinib through BTK inhibition and umbralisib, an experimental inhibitor of PI3K.

October 4, 2021

ASCO 2021 Top Pick #6: Fixed Duration (FD) First-Line Treatment with Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the FD Cohort of the Phase 2 CAPTIVATE Study

The CAPTIVATE study data has been highly anticipated. At ASH 2020, we got important results. Dr. Wierda presented the results of Minimal (Measurable) Residual Disease (MRD) cohort using MRD status to guide therapy: Undetectable MRD (uMRD) was achieved in >2/3 of patients with 12 cycles of I+V, and the

October 4, 2021

EHA 2021 Top Pick #5: Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase I/II BRUIN Study

Dr. Lindsey Roeker of MSKCC, NYC, NY presented results at 2021 European Hematology Association Virtual Congress, (EHA 2021).

October 4, 2021

EHA 2021 Top Pick #4: First Interim Analysis of the ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This was accepted as a late breaking abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021), reflecting its importance to the best management of relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL). Investigators from multiple CLL centers in Europe, Australia, and North America were involved in this research.